Paris and Tarrytown, NY - March 2, 2018 - The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application of Dupixent ® (dupilumab) as an add-on ...
Most people with asthma are able to control their symptoms by using inhaled medicines each day. But for some people with severe asthma, inhaled medicines are not enough to keep symptoms under control.
Regeneron and Sanofi are back with another push to show how Dupixent can help people with asthma “Du More.” The fourth generation of the campaign dials up the humor to try to connect with patients on ...
Approval based on global phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function compared to placebo (by 4.68% to 5.32%) ...
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results